ERBB2 and breast cancer: The highly aggressive triple negative breast cancer (TNBC), with a prevalence of 15% of breast cancer cases often presenting in younger patients, is characterised by tumours that lack expression of ER, progesterone receptor and HER2/neu and is associated with a poor clinical prognosis [3].